Toreforant

• CAT Number: I009851
• CAS Number: 952494-46-1
• Molecular Formula: C23H32N6
• Molecular Weight: 392.55
• Purity: ≥95%
• Synonyms: JNJ-38518168; JNJ 38518168; JNJ38518168; Toreforant.;5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl- N-[3-(1-methylpiperidin-4-yl)propyl]pyrimidin-2-amine
• Target: Neuronal Signaling
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: 5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-[3-(1-methylpiperidin-4-yl)propyl]pyrimidin-2-amine
• InChI: InChI=1S/C23H32N6/c1-15-12-16(2)21-20(13-15)27-22(28-21)19-14-25-23(26-17(19)3)24-9-5-6-18-7-10-29(4)11-8-18/h12-14,18H,5-11H2,1-4H3,(H,27,28)(H,24,25,26)
• InChIKey: FCRFVPZAXGJLPW-UHFFFAOYSA-N
• SMILES: CC1=CC(=C2C(=C1)NC(=N2)C3=CN=C(N=C3C)NCCCC4CCN(CC4)C)C

Toreforant(CAT: I009851) is a selective Janus kinase 1 and 3 (JAK1/JAK3) inhibitor designed to modulate the JAK-STAT signaling pathway, which plays a crucial role in immune response and inflammation. By inhibiting JAK1 and JAK3, Toreforant reduces the activity of pro-inflammatory cytokines, making it a promising candidate for treating autoimmune and inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease (IBD). Toreforant’s targeted mechanism offers potential for suppressing abnormal immune activation while minimizing off-target effects, positioning it as a valuable compound in immunology research and the development of therapies for chronic inflammatory conditions.